INS 5010
Alternative Names: INS-5010Latest Information Update: 28 May 2024
At a glance
- Originator Inositec
- Class Antibacterials; Antitoxins; Inositol phosphates; Small molecules; Sugar alcohols
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Clostridium difficile infections
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Clostridium-difficile-infections in Switzerland (PO)
- 29 Apr 2020 INS 5010 is available for licensing as of 29 Apr 2020. http://inositec.com/pipeline/
- 29 Apr 2020 Early research in Clostridium difficile infections in Switzerland (PO), before April 2020 (Inositec pipeline, April 2020)